Insulet Corporation shares have fallen 36.7% over the past three months, while the broader State Street Health Care Select Sector SPDR ETF gained 1.5% in the same period. The stock is down 51.7% over the past 52 weeks and 48.7% year-to-date, compared with a 12.1% gain and a 3.5% decline for the sector ETF, respectively. Despite the underperformance, the company raised its full-year 2026 revenue growth guidance to 21% to 23% and announced a U.S. rollout of algorithm enhancements for its Omnipod 5 AID system. Wall Street analysts maintain a consensus Strong Buy rating with a mean price target of $237.56, implying a 63% upside from current levels.
Insulet CorporationRaised full-year 2026 revenue growth guidance to 21%-23% and announced U.S. rollout of algorithm enhancements for Omnipod 5 AID system.
Zimmer Biomet Holdings Inc